

Devyser Genomic Laboratories signs first commercial agreement

Devyser Genomic Laboratories, Devyser's US-based CLIA-certified laboratory, has signed its first commercial agreement with UK based diagnostics company Cytel. The initial period for the agreement is two years with estimated total revenue amounting up to approximately 25 MSEK where of approximately up to 6 MSEK in 2024.

Devyser CEO Fredrik Alpsten commented: *"This agreement, our first external commercial agreement, shows the large potential with our state-of-the-art CLIA-certified Next Generation Sequencing laboratory. Running tests for partners is one of the main purposes of the laboratory. The other main purpose of the laboratory is to offer tests to hospitals and laboratories as a service".*

Cytel CEO and Co-Founder Marcel Gehring commented: *"This is an important step as Cytel expands its operations into the United States. Devyser Genomic Laboratories' expertise and capabilities will be pivotal as we introduce the Heartburn Health Check using our minimally invasive test, EndoSign®, into new markets. I look forward to working with the team and delivering to those who would benefit from our innovative diagnostic technology."*

Devyser established the US CLIA-certified laboratory, Devyser Genomic Laboratories (<https://lab.devyser.com>), during the spring of 2023 and received CLIA certification from the Centers for Medicare and Medicaid Services (CMS) in May 2023. The laboratory is based in Atlanta, Georgia.

For more information, please contact:

Fredrik Alpsten, CEO

E-mail: fredrik.alpsten@devyser.com

Telephone: +46 70 667 31 06

Theis Kipling, CCO

E-mail: theis.kipling@devyser.com

Telephone: +46 73 598 07 76



PRESS RELEASE

17 January 2024 11:30:00 CET

About Devyser

Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.

For more information, visit www.devyser.com.

About Cytel

Cytel is a gastrointestinal health company that has created a non-endoscopic diagnostic platform to detect disease early and save lives. Our technologies are transforming access to digestive health for everyone, everywhere.

Cytel's technology brings earlier and faster diagnoses to more people, helping to detect and monitor those with cancer and inflammatory diseases before it is too late.

Cytel website: <https://cyted.ai>